Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, comments on her study assessing clinical outcomes up to 9 years after amyloid-PET in a symptomatic memory clinic population. Mortality rate was comparable in the amyloid-positive and amyloid-negative groups, but clinical decline was faster in the amyloid-positive cohort, reflected by MMSE, episodic memory, and fluency scores. Clinical etiological diagnosis was consistent with baseline in most patients, with no amyloid-negative patients receiving an Alzheimer’s disease diagnosis during follow-up. In all cases with neuropathological data available, amyloid-PET ruling was in line with post-mortem findings. These data support the validity of amyloid-PET. This interview took place at the CTAD 2023 conference in Boston, MA.
For more on the AMYPAD consortium: amypad.eu
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
